Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 89 Gastrointestinal 87 Genitourinary 78 Thoracic 52 Head & Neck 42 Other hematologic neoplasm 37 Tumor-Agnostic 31 Gynecologic 30 Lymphoid 21 CNS 21 Other solid neoplasm 17 Dermatologic 12 Plasma cell 11 Other 10 Sarcoma 9 Myeloid 5 Endocrine 5 Classical hematology 2 Other neoplasm 1 NET 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 41 Everolimus 38 Magnetic Resonance Spectroscopy 18 Temozolomide 17 lanreotide 16 gallium Ga 68 dotatate 15 Octreotide 14 pembrolizumab 13 Nivolumab 13 Capecitabine 12 cabozantinib 11 177Lu-octreotide, DOTA(0)-Tyr(3)- 11 surufatinib 9 pasireotide 9 Sunitinib 9 Specimen Handling 9 Positron Emission Tomography Computed Tomography 9 3-Iodobenzylguanidine 9 Lutetium-177 8 Carboplatin 8 amino-acid, glucose, and electrolyte solution 6 Ipilimumab 6 Ga(III)-DOTATOC 6 Fluorodeoxyglucose F18 6 Etoposide 6 Cisplatin 6 90Y-octreotide, DOTA-Tyr(3)- 6 lenvatinib 5 copper dotatate CU-64 5 Injections 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Standard of Care × NET × Clear all

NCT02472678 2024-05-06

WIN

University Medical Center Groningen

Phase NA Completed

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡